title: [Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy].
abstract: Cytokines were the only drugs proven to be effective for advanced renal cell carcinoma(RCC). Introducing the targeted drugs prolonged patients' survival. However, limited high-quality evidence is now available for second-line treatment. Everolimus is effective for patients who have experienced progression of disease after sunitinib and/or sorafenib. Further prospective study including the sequencing of targeted drugs is warranted to develop better treatment strategies.
authors.affiliation: Dept. of Urology, Yamagata University Faculty of Medicine.
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Tomita
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D058990:Molecular Targeted Therapy; D016032:Randomized Controlled Trials as Topic; D016879:Salvage Therapy
chemical_list: D000970:Antineoplastic Agents